Susquehanna International Group’s Dyne Therapeutics DYN Stock Holding History

Susquehanna International Group’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.03M	Sell	111,900 -83,100	-43%	-$1.43M	﹤0.01%	6149
2025 Q4	$3.81M	Buy	195,000 +105,700	+118%	+$2M	﹤0.01%	4483
2025 Q3	$1.13M	Buy	89,300 +72,600	+435%	+$828K	﹤0.01%	7052
2025 Q2	$159K	Sell	16,700 -20,900	-56%	-$230K	﹤0.01%	11456
2025 Q1	$393K	Sell	37,600 -25,300	-40%	-$362K	﹤0.01%	9433
2024 Q4	$1.48M	Buy	62,900 +16,000	+34%	+$473K	﹤0.01%	5982
2024 Q3	$1.68M	Buy	46,900 +27,900	+147%	+$1.11M	﹤0.01%	5635
2024 Q2	$671K	Sell	19,000 -86,700	-82%	-$2.52M	﹤0.01%	7540
2024 Q1	$3M	Buy	105,700 +68,200	+182%	+$1.54M	﹤0.01%	4514
2023 Q4	$499K	Buy	+37,500	New	+$366K	﹤0.01%	8673
2023 Q3	–	Sell	-12,000	Closed	-$135K	–	12208
2023 Q2	$135K	Buy	+12,000	New	+$142K	﹤0.01%	10675

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Susquehanna International Group's DYN Position: Q1 2026 in Review

Susquehanna International Group increased its Dyne Therapeutics (DYN) stake by 11% in Q1 2026, buying an estimated $181K and bringing the position to 108,724 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #6207.

Susquehanna International Group first reported a position in DYN in Q1 2021 and has held it in 16 quarters since. The position peaked at $12.5M in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Susquehanna International Group held 108,724 shares of Dyne Therapeutics worth $1.97M as of Q1 2026.
Susquehanna International Group bought 10,509 Dyne Therapeutics shares in Q1 2026, an estimated $181K.
Dyne Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6207 holding.
Susquehanna International Group first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 16 quarters since.
Susquehanna International Group's Dyne Therapeutics position peaked at $12.5M in Q1 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.